Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Profile Name FGFR2 - WAC
Gene Variant Detail

FGFR2 - WAC (unknown)

Relevant Treatment Approaches


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FGFR2 - WAC intrahepatic cholangiocarcinoma predicted - sensitive Futibatinib Case Reports/Case Series Actionable In a Phase I trial, Futibatinib (TAS-120) treatment at a dose of 16mg led to a partial response in 42.1% (8/19) of patients with intrahepatic cholangiocarcinoma harboring FGF or FGFR alterations, including a partial response with a progression-free survival of 6.9 months and a duration of response of 4.2 months in a patient harboring FGFR2-WAC (PMID: 34551969; NCT02052778). 34551969
FGFR2 - WAC cholangiocarcinoma predicted - sensitive Infigratinib Case Reports/Case Series Actionable In a clinical case study, treatment with Truseltiq (infigratinib) resulted in a partial response in a patient with cholangiocarcinoma harboring an FGFR2-WAC fusion (PMID: 34250419). 34250419
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries